Key result
Dual siRNA severely limits HCV escape mutant evolution compared with single siRNA.
Why the study?
RNA interference using siRNA targeting the HCV genome shows incomplete blockade of viral replication due to emergence of resistant replicon RNAs.
Does siRNA targeting the HCV genome block replication and prevent escape mutant evolution in human liver cells?
Does siRNA targeting the HCV genome block replication and prevent escape mutant evolution in human liver cells?
A combination of multiple siRNAs can prevent the emergence of resistant HCV replicons, suggesting a potential therapeutic strategy for HCV.
Answers are grounded in this paper and cite their sources.
siRNA inhibits HCV replication in hepatoma cells; leaves open clinical translation of RNAi therapeutics in patients.
RNA interference represents an exciting new technology that could have therapeutic applications for the treatment of viral infections. Hepatitis C virus (HCV) is a major cause of chronic liver disease and affects over 270 million individuals worldwide. The HCV genome is a single-stranded RNA that functions as both an mRNA and a replication template, making it an attractive target for therapeutic approaches using short interfering RNA (siRNA). We have shown previously that double-stranded siRNA molecules designed to target the HCV genome block gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. However, we now show that this block is not complete. After several treatments with a highly effective siRNA, we have shown growth of replicon RNAs that are resistant to subsequent treatment with the same siRNA. However, these replicon RNAs were not resistant to siRNA targeting another part of the genome. Sequence analysis of the siRNA-resistant replicons showed the generation of point mutations within the siRNA target sequence. In addition, the use of a combination of two siRNAs together severely limited escape mutant evolution. This suggests that RNA interference activity could be used as a treatment to reduce the devastating effects of HCV replication on the liver and the use of multiple siRNAs could prevent the emergence of resistant viruses.
No takes yet. Share an insight, caveat, or question.
Wilson et al. (2005) studied Hepatitis C virus infection. short interfering RNA (siRNA) was evaluated on HCV replicon RNA growth and resistance. Treatment of HCV replicons with a single siRNA led to the emergence of resistant point mutations, whereas a combination of two siRNAs severely limited escape mutant evolution.
Synapse has enriched 10 related papers. Consider them for comparative context: